CycLex SIRT2 Deacetylase Fluorometric Assay Kit Ver.2

MBL
Product Code: MBL-CY-1152V2
Supplier: MBL
CodeSizePrice
MBL-CY-1152V2100 Assays£541.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
Dry Ice
Storage:
-70°C

Images

1 / 2
2 / 2

Documents

Further Information

Background:
Sir2 is a conserved protein and was recently shown to regulate lifespan extension both in budding yeast and nematode. In 2000, it was reported that the yeast Sir2 protein is a NAD(+)-dependent histone deacetylase that plays a critical role in transcriptional silencing, genome stability and longevity. In mammals, the homologs of Sir2 have been named sirtuins (SIRT), with seven members in a family termed SIRT1 through SIRT7. They share a conserved central deacetylase domain but have different Nand C termini and display distinct subcellular localization, suggesting different biological functions (1). In contrast to SIRT1, mammalian SIRT2 is localized mainly in the cytoplasm. SIRT2 colocalizes with the microtubule network and deacetylates Lys40 of alpha-tubulin (2). The same residue of alpha-tubulin is also deacetylated by HDAC6, a class II HDAC, and deacetylation by HDAC6 leads to changes in cellular motility (3). A role for SIRT2 in cancer pathogenesis was demonstrated using a proteomic approach (4). The SIRT2 gene, which is located at chromosome 19q13.2, lies within a region that is frequently deleted in human gliomas, and levels of SIRT2 mRNA and protein expression are severely reduced in a large fraction of human glioma cell lines (4). Ectopic expression of SIRT2 in these cell lines suppressed colony formation and modified the microtubule network. These results indicate that SIRT2 may act as a tumor suppressor and may function to control the cell cycle by acetylation of alpha-tubulin. It was reported that SIRT2 inhibitor rescued alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson?s disease, however the exact mechanism remains uncertain. However, the conventional method for measuring SIRT2 activity is very complicated and laborious. In order to measure SIRT2 enzyme activity, it is necessary to prepare radioactive acetylated histone H4 as a substrate. First, cells have to be labeled metabolically with radioactivity by adding radioactive acetic acid to the culture medium. Second, radioactive acetylated histone has to be purified from the cells. Following the reaction, it is necessary to extract and separate the radioactive acetyl group, which has been released from acetylated histone, using ethyl acetate to measure the activity of the enzyme based on the radioactivity. Although a method for measuring the activity of deacetylase without the use of radioactive substances was reported in recent years, owing to the use of fluorescent-labeled acetylated lysine as a substrate, the reaction product must be separated from the intact substrate and the fluorescent intensity measured by reverse phase HPLC. As mentioned above, these measurement systems are difficult to adapt for processing many samples under a variety of conditions, because of their complicated operation. Thus a simple system for biochemical analysis as well as for inhibitor screening without the use of radioactive substances is preferred.
Description:
This kit is designed for the rapid and sensitive evaluation of SIRT2 inhibitors or activators using recombinant SIRT2 or purified SIRT2
Kit Components:
SIRT2 Assay Buffer, Fluoro-Substrate Peptide (0.2 mM), Fluoro-Deacetylated Peptide (0.2 mM), NAD (8 mM), Developer, Recombinant SIRT2, Stop Solution
Shelf Life:
1 year
Target:
SIRT2

References

1. North, B.J., and Verdin, E.; Sirtuins: SIRT2-related NAD-dependent protein deacetylases. Genome Biol. 5: 224, 2004 2. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E; The human SIRT2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11:437-444, 2003 3. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP; HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458, 2002 4. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CG, Kurimasa A, Oshimura M; Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. BBRC 309: 558-566, 2003 5. S Imai, CM Armstrong, M Kaeberlein, and L Guarente; Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403: 795-800, 2000 6. Joseph Landry, Ann Sutton, Stefan T. Tafrov, Ryan C. Heller, John Stebbins, Lorraine Pillus, and Rolf Sternglanz; The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases Proc Natl Acad Sci U S A 97: 5807-5811, 2000 7. Jeffrey S. Smith, Carrie Baker Brachmann, Ivana Celic, Margaret A. Kenna, Shabazz Muhammad, Vincent J. Starai, Jose L. Avalos, Jorge C. Escalante-Semerena, Charles Grubmeyer, Cynthia Wolberger, and Jef D. Boeke; A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family Proc Natl Acad Sci U S A 97, 6658-6663, 2000 8. H Vaziri, SK Dessain, E Ng Eaton, SI Imai, RA Frye, TK Pandita, L Guarente, and RA Weinberg; hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107: 149-159, 2001 9. J Luo, AY Nikolaev, S Imai, D Chen, F Su, A Shiloh, L Guarente, and W Gu; Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107: 137-148, 2001 10. E Langley, M Pearson, M Faretta, UM Bauer, RA Frye, S Minucci, PG Pelicci, and T Kouzarides; Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21: 2383-2396, 2002 11. J Smith; Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 12: 404, 2002 12. CM Grozinger and SL Schreiber; Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol, 9: 3-16, 2002